JPRN-jRCT2031230115招募中2 期
A phase II clinical trial of KNP2002 ointment in patients with common warts
Sato Katsuhiko0 个研究点目标入组 160 人开始时间: 2023年6月7日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 15age old 至 < 50age old（—）
- 性别
- All
入选标准
- •1. Subjects aged 15 to 49 at the time of obtaining consent
- •2. Subjects with typical common warts on the upper extremities or lower extremities excluding the soles of the feet.
- •3. Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration
- •4. Subjects who have given their voluntary written consent to participate in this clinical trial
排除标准
- •1. Subjects with 5 or more warts due to human papillomavirus (HPV) infection on the upper or lower limbs
- •2. Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts
- •3. Subjects with a history of allergy to topical skin preparations
- •4. Subjects with a history of malignant tumor within 5 years before administration of study drug
- •5. Subjects with any of the following diseases
- •Malignant tumor
- •Serious heart disease
- •Poorly controlled diabetes, hypertension
- •6. Women who are pregnant, may become pregnant, or are breastfeeding.
研究者
相似试验
未知
2 期
K012 phase II clinical studyColorectal cancerJPRN-jRCT2080220752ippon Kayaku Co., Ltd.
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ATInternational Breast Cancer Study Group (IBCSG)61
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregionalor metastatic breast carcinoma which has progressed on priortrastuzumab-based therapyMedDRA version: 17.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-ITInternational Breast Cancer Study Group (IBCSG)58
进行中（未招募）
1 期
A phase Ib/II trial evaluating the efficacy of the antibody MK-3475 and standard therapy trastuzumab in patients with trastuzumab-resistant, HER2-positive advanced breast cancersPatients with HER2-positive, PD-L1 expressing, unresectable locoregional or metastatic breast carcinoma which has progressed on prior trastuzumab-based therapy.A parallel cohort of 15 patients with HER2-positive, PD-L1 negative disease will be enrolled in the phase II study.MedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2013-004770-10-BEInternational Breast Cancer Study Group (IBCSG)61
尚未招募
2 期
Phase II Clinical Trial: Efficacy and Safety of Kaempferia Parviflora in Treatment of Chronic Vertigo PatientsDizzinessKaempferia parviflora,chronic vertigo,Dizziness Handicap Inventory,Vestibular functionTCTR20181122001Agricultural Research Development Agency (Public Organization)72